Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Receivables (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Change in Receivables for 15 consecutive years, with $368000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $368000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $320000.0, a 281.82% increase, with the full-year FY2024 number at -$291000.0, up 65.6% from a year prior.
  • Change in Receivables was $368000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from -$48000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.0 million in Q3 2022 to a low of -$1.4 million in Q3 2023.
  • A 5-year average of -$61066.7 and a median of -$68000.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 1029.41% in 2022; the steepest drop was 719.59% in 2022.
  • NovaBay Pharmaceuticals' Change in Receivables stood at -$189000.0 in 2021, then increased by 15.34% to -$160000.0 in 2022, then soared by 141.88% to $67000.0 in 2023, then tumbled by 171.64% to -$48000.0 in 2024, then skyrocketed by 866.67% to $368000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Change in Receivables are $368000.0 (Q3 2025), -$48000.0 (Q4 2024), and -$243000.0 (Q1 2024).